What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Liquid Biopsy: A Non-Invasive Window into Cancer

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Cancer has traditionally been diagnosed and monitored through tissue biopsies—procedures in which a surgeon or radiologist removes a small piece of a suspected tumor for laboratory analysis. While tissue biopsy remains a cornerstone of oncology, it has significant limitations: it is invasive, painful, carries risks of bleeding and infection, and provides only a snapshot of a single tumor location at a single moment in time. Tumors, however, are not static; they evolve, mutate, and develop resistance to treatment. What if we could sample a tumor's genetic information simply by drawing blood? That is the promise of liquid biopsy.

What Is Liquid Biopsy?

A liquid biopsy is a laboratory test performed on a sample of body fluid—most commonly blood, but also urine, cerebrospinal fluid, or saliva—to detect and analyze cancer-derived material. Instead of removing tumor tissue directly, a liquid biopsy captures the molecular traces that tumors shed into circulation. These traces include fragments of DNA released by dying tumor cells, intact tumor cells that have broken away from the primary mass, and membrane-bound vesicles that carry tumor-derived cargo.

The term "biopsy" is borrowed from the traditional procedure, but the contrast is stark. A tissue biopsy requires a needle, a scalpel, or an endoscope to physically access the tumor. A liquid biopsy requires only a standard blood draw, similar to routine blood tests for cholesterol or blood sugar. The sample is then processed in a laboratory to isolate and analyze the cancer-related components within it.

The conceptual foundation of liquid biopsy rests on a simple biological fact: tumors are not static, isolated masses. They are dynamic, growing, and constantly remodeling their environment. As tumor cells divide, die, and metastasize, they release genetic material and whole cells into the bloodstream. This circulating material carries the same Genetic Mutation signatures as the tumor itself, effectively providing a real-time molecular portrait of the cancer without requiring invasive sampling.

Why Liquid Biopsy Matters

The advantages of liquid biopsy over traditional tissue biopsy are substantial and have driven intense research and clinical adoption.

Non-invasive and safe. A blood draw carries minimal risk. There is no surgical incision, no anesthesia, no risk of bleeding, infection, or damage to surrounding tissues. Patients can undergo liquid biopsy as frequently as clinically indicated without cumulative harm.

Repeatable and dynamic. Cancer is not a static disease. Tumors evolve under the selective pressure of treatment, acquiring new mutations that confer drug resistance. A tissue biopsy provides a single time point, often taken at initial diagnosis. If the tumor changes months later, the original biopsy may no longer reflect the cancer's current biology. Liquid biopsy can be repeated at any time—before treatment, during treatment, at suspected progression—allowing oncologists to track the tumor's molecular evolution in real time.

Captures tumor heterogeneity. A tissue biopsy samples one small region of one tumor. But a patient may have multiple metastatic lesions in different organs, each with distinct genetic profiles. Liquid biopsy samples the pooled contribution of all tumor sites, providing a more comprehensive view of the cancer's overall genetic landscape.

Potential for early detection. Because liquid biopsy can detect tiny amounts of tumor-derived DNA in the bloodstream, it holds promise for identifying cancer at earlier stages, when treatment is more likely to be effective. This is an area of active research, with multi-cancer early detection tests currently in development.

Feasibility when tissue is inaccessible. Some tumors are located in difficult-to-reach areas—deep within the lungs, brain, or pancreas—where surgical biopsy carries high risk. Liquid biopsy offers an alternative when tissue sampling is not feasible or has failed to yield sufficient diagnostic material.

What Can Be Detected in a Liquid Biopsy?

Liquid biopsy assays target several classes of tumor-derived material, each with distinct biological characteristics and clinical applications.

Circulating Tumor DNA (ctDNA)

Circulating tumor DNA, or ctDNA, is fragmented DNA released into the bloodstream when tumor cells die—either through apoptosis (programmed cell death) or necrosis (uncontrolled cell death). These fragments are typically 130 to 180 base pairs in length, corresponding to the size of DNA wrapped around a nucleosome, the basic unit of chromatin packaging. In healthy individuals, the blood contains cell-free DNA (cfDNA) released by normal cells, but the concentration of ctDNA specifically reflects the presence and burden of tumor cells.

ctDNA carries the same mutations, copy number alterations, and epigenetic modifications as the tumor from which it originated. If a tumor harbors a mutation in the EGFR gene, for example, that same mutation can be detected in the patient's blood. The fraction of ctDNA relative to total cfDNA varies widely, from less than 0.01% in early-stage disease to over 50% in advanced, high-burden cancers. This dynamic range makes ctDNA both a sensitive biomarker and a quantitative measure of tumor burden.

The biological basis of ctDNA release is directly tied to the Molecular Mechanism of Cancer. Tumor cells are genetically unstable, accumulating mutations that drive uncontrolled proliferation. As these cells outgrow their blood supply, they undergo necrosis and apoptosis, releasing their DNA into the extracellular space. This DNA then enters the bloodstream through the lymphatic system and capillary beds. The process is continuous, meaning ctDNA levels reflect ongoing tumor activity rather than a historical snapshot.

Circulating Tumor Cells (CTCs)

Circulating tumor cells are intact, viable cancer cells that have detached from the primary tumor or metastatic sites and entered the bloodstream. They are extraordinarily rare—typically 1 to 10 CTCs per 10 million white blood cells in patients with metastatic cancer. Their presence in the blood is a prerequisite for metastasis, as these cells travel through the circulation to seed distant organs.

CTCs are larger than most blood cells and express epithelial surface markers such as EpCAM (epithelial cell adhesion molecule), which can be used to capture them from blood samples. Once isolated, CTCs can be counted, stained, and analyzed for protein expression, or their DNA and RNA can be extracted for genomic analysis. CTC enumeration has prognostic value: in metastatic breast, prostate, and colorectal cancer, higher CTC counts correlate with worse overall survival.

Unlike ctDNA, which represents DNA from dead cells, CTCs are living cells. This distinction matters because CTCs can be cultured in the laboratory or implanted into mice to create patient-derived xenograft models, enabling functional studies of drug sensitivity. However, CTCs are far more difficult to capture than ctDNA, and their rarity limits their clinical utility in early-stage disease.

Exosomes and MicroRNAs

Exosomes are small membrane-bound vesicles, 30 to 150 nanometers in diameter, released by all cells—including tumor cells—into the extracellular space. They carry proteins, lipids, messenger RNA (mRNA), and microRNAs (miRNAs), and they play a role in intercellular communication. Tumor-derived exosomes can influence the local microenvironment, promote angiogenesis, and prepare distant sites for metastasis.

MicroRNAs are short, non-coding RNA molecules, approximately 19 to 25 nucleotides in length, that regulate gene expression by binding to complementary sequences on target mRNAs, typically leading to mRNA degradation or translational repression. Specific miRNA signatures are altered in various cancers, and these molecules are remarkably stable in blood because they are protected from degradation by their packaging within exosomes or by association with proteins such as Argonaute 2.

The clinical utility of exosomes and miRNAs is less established than that of ctDNA and CTCs, but they offer unique advantages. Exosomes are actively secreted by tumor cells, meaning their composition may reflect not just cell death but also active tumor biology. miRNAs can be detected in very small sample volumes and are stable through freeze-thaw cycles, making them attractive biomarkers. However, the field faces challenges in standardizing isolation methods and distinguishing tumor-derived exosomes from those released by normal cells.

How Does Liquid Biopsy Work?

The workflow for liquid biopsy involves several distinct steps, each with its own technical challenges and quality control requirements.

Sample Collection and Processing

The most common sample type is peripheral blood, collected in tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. EDTA prevents clotting but does not stabilize cells indefinitely; cell lysis after collection releases genomic DNA from white blood cells, which can dilute and contaminate the ctDNA fraction. For this reason, blood samples must be processed within a few hours of collection, or collected in specialized tubes containing preservatives such as Streck Cell-Free DNA BCT tubes, which stabilize cfDNA for up to 14 days at room temperature.

Upon arrival at the laboratory, the blood is subjected to centrifugation—typically at 1,600 × g for 10 minutes at 4°C—to separate plasma from cellular components. The plasma layer, which contains cfDNA, CTCs, and exosomes, is carefully removed and either analyzed immediately or stored at −80°C. For ctDNA analysis, a second high-speed centrifugation step (16,000 × g for 10 minutes) removes residual cellular debris and platelets.

Isolation of Biomarkers

The method of biomarker isolation depends on the target analyte.

ctDNA extraction. Cell-free DNA is extracted from plasma using commercial kits based on silica column chromatography or magnetic bead technology. These kits typically use chaotropic salts to denature proteins and promote DNA binding to the silica matrix, followed by washing steps to remove contaminants and elution in a low-salt buffer. Typical yields from a 4 mL plasma sample range from 10 to 100 nanograms of total cfDNA, of which ctDNA may represent only a small fraction.

CTC capture. CTCs are isolated using methods that exploit their physical or biological properties. The FDA-approved CellSearch system uses magnetic beads coated with antibodies against EpCAM to capture epithelial cells from whole blood. The captured cells are then stained with fluorescent antibodies against cytokeratins (epithelial markers) and CD45 (a leukocyte marker) to distinguish CTCs from contaminating white blood cells. Alternative approaches use microfluidic devices that separate CTCs based on size (they are typically larger than leukocytes) or deformability.

Exosome isolation. Exosomes are commonly isolated by ultracentrifugation at 100,000 × g for 70 to 90 minutes, which pellets the vesicles. More recent methods use size-exclusion chromatography, polymer-based precipitation, or immunoaffinity capture with antibodies against exosomal surface proteins such as CD63, CD81, and CD9. Each method has trade-offs between purity, yield, and preservation of exosome integrity.

Analysis and Interpretation

Once isolated, biomarkers are analyzed using molecular techniques that detect specific genetic alterations.

Polymerase chain reaction (PCR). PCR is the workhorse of ctDNA analysis. Digital PCR (dPCR) partitions a sample into thousands of nanoliter-scale reactions, each containing at most one DNA template molecule. By counting the number of partitions that show a positive signal for a mutant allele, dPCR can quantify the fraction of mutant DNA with remarkable precision—detecting mutations present at frequencies as low as 0.01%. This sensitivity is essential because ctDNA often constitutes less than 1% of total cfDNA.

Real-time quantitative PCR (qPCR) is also used, particularly for detecting specific point mutations such as EGFR T790M in non-small cell lung cancer. The assay uses allele-specific primers or probes that preferentially amplify the mutant sequence, and the cycle threshold (Ct) value reflects the initial quantity of mutant DNA.

Next-generation sequencing (NGS). NGS allows simultaneous analysis of multiple genes, enabling detection of point mutations, insertions, deletions, copy number alterations, and structural rearrangements. Targeted NGS panels, which focus on the exons of 50 to 500 cancer-related genes, are most commonly used because they offer high sequencing depth (typically 10,000× or greater) at manageable cost. The high depth is critical for detecting low-frequency mutations in a background of normal cfDNA.

The sequencing process involves several steps: library preparation (ligating adapters to DNA fragments), amplification, clonal amplification on a flow cell, and sequencing by synthesis. The resulting data are aligned to the human reference genome, and variant calling algorithms identify positions where the sequence differs from the reference. The variant allele frequency (VAF)—the proportion of sequencing reads carrying a mutation—provides a quantitative measure of ctDNA level.

Methylation analysis. DNA methylation—the addition of a methyl group to cytosine residues in CpG dinucleotides—is an epigenetic modification that is frequently altered in cancer. Hypermethylation of promoter regions in Tumor Suppressor Gene such as p16 (also known as CDKN2A) or MGMT silences their expression, contributing to tumor development. Methylation-specific PCR (MSP) uses primers that distinguish methylated from unmethylated DNA after bisulfite conversion, a chemical treatment that converts unmethylated cytosines to uracil while leaving methylated cytosines intact. Genome-wide methylation analysis can also be performed using arrays or bisulfite sequencing.

Types of Liquid Biopsy Tests

Several types of liquid biopsy tests are used in clinical practice and research, each designed to answer specific clinical questions.

Test Type	Target	Method	Clinical Use
ctDNA mutation analysis	Specific point mutations (e.g., EGFR, KRAS, BRAF)	Digital PCR or targeted NGS	Treatment selection, resistance monitoring
CTC enumeration	Intact circulating tumor cells	Immunomagnetic capture (CellSearch)	Prognosis in metastatic cancer
Methylation-based assays	Promoter methylation of tumor suppressor genes	Methylation-specific PCR	Early detection, minimal residual disease
Exosomal RNA analysis	mRNA and miRNA within exosomes	RNA extraction and qPCR/NGS	Research, emerging clinical applications
Whole-genome sequencing of ctDNA	Copy number alterations, structural variants	Low-pass whole-genome sequencing	Tumor burden estimation, tissue-of-origin inference

The most widely used clinical test is ctDNA mutation analysis for actionable mutations—genetic alterations for which targeted therapies exist. For example, in non-small cell lung cancer, detection of EGFR mutations (such as exon 19 deletions or L858R point mutations) in ctDNA can guide treatment with tyrosine kinase inhibitors like erlotinib or osimertinib. Similarly, detection of KRAS mutations in colorectal cancer predicts lack of response to anti-EGFR antibody therapies such as cetuximab.

CTC enumeration using the CellSearch system is FDA-approved for monitoring patients with metastatic breast, prostate, and colorectal cancer. A CTC count of 5 or more per 7.5 mL of blood in metastatic breast cancer is associated with shorter progression-free and overall survival compared with counts below 5.

Methylation-based assays are less commonly used in routine clinical practice but are a focus of research for early cancer detection. The Epi proColon test, which detects methylation of the SEPT9 gene in plasma, is FDA-approved for colorectal cancer screening. The test has a sensitivity of approximately 68% for detecting colorectal cancer, with higher sensitivity for later-stage disease.

Clinical Applications of Liquid Biopsy

Liquid biopsy has moved from research laboratories into clinical practice across several domains of oncology.

Diagnosis and early detection. Liquid biopsy is not yet used for general population screening, but it has shown promise in specific contexts. For patients with suspected cancer who cannot undergo tissue biopsy, ctDNA analysis can provide a molecular diagnosis. In cases where a tissue biopsy yields insufficient material for genetic testing—a common problem in lung cancer, where up to 30% of biopsies are non-diagnostic—liquid biopsy can serve as a complementary approach.

Treatment selection. The most established clinical application is the detection of actionable mutations to guide targeted therapy. In non-small cell lung cancer, the FDA has approved several liquid biopsy tests for detecting EGFR mutations, including the cobas EGFR Mutation Test v2. When a patient's tumor harbors an activating EGFR mutation, treatment with EGFR tyrosine kinase inhibitors improves response rates and progression-free survival compared with chemotherapy.

Monitoring treatment response. ctDNA levels correlate with tumor burden and can change rapidly in response to treatment. A decrease in ctDNA concentration within weeks of starting therapy indicates a response, while rising levels suggest progression. This dynamic information can complement or, in some cases, replace radiographic imaging for assessing treatment efficacy. In clinical trials, ctDNA-based response assessment has been shown to detect progression weeks to months earlier than computed tomography (CT) scans.

Detecting resistance. Tumors that initially respond to targeted therapy almost invariably develop resistance through new mutations. In lung cancer treated with first-generation EGFR inhibitors, resistance often arises through the T790M mutation in EGFR, which prevents drug binding. Liquid biopsy can detect T790M in ctDNA, guiding the switch to third-generation inhibitors like osimertinib that are active against this resistant clone. Similarly, in colorectal cancer treated with anti-EGFR antibodies, acquired mutations in KRAS or NRAS can be detected in ctDNA before radiographic progression.

Detecting recurrence. After curative-intent surgery, ctDNA can be used to detect minimal residual disease—the presence of tiny numbers of tumor cells that remain after treatment. Patients with detectable ctDNA after surgery are at high risk of recurrence, and ctDNA-based surveillance can identify recurrence months before it becomes visible on imaging. This application is particularly advanced in colorectal cancer, where post-operative ctDNA positivity is strongly associated with disease recurrence.

Evidence and Research Behind Liquid Biopsy

The clinical adoption of liquid biopsy is supported by a substantial body of evidence from clinical trials and observational studies.

The FDA has approved several liquid biopsy tests. The cobas EGFR Mutation Test v2 was approved in 2016 for detecting EGFR mutations in plasma from patients with non-small cell lung cancer, with the indication that a negative result should be confirmed by tissue testing. The Epi proColon test for colorectal cancer screening was approved in 2016. The FoundationOne Liquid CDx test, approved in 2020, is a comprehensive genomic profiling assay that detects mutations in 324 genes from plasma and is approved for use in multiple cancer types.

Large prospective studies have validated the clinical utility of ctDNA monitoring. In the field of colorectal cancer, studies have shown that ctDNA detection after surgery identifies patients at high risk of recurrence with high accuracy. In lung cancer, clinical trials have demonstrated that ctDNA-based detection of the T790M resistance mutation can guide treatment decisions with outcomes comparable to tissue-based testing.

Research is also advancing toward multi-cancer early detection. The Galleri test, developed by GRAIL, uses targeted methylation analysis of cfDNA to detect cancer signals and predict the tissue of origin. In a study of over 6,000 participants, the test detected cancer signals with a specificity of 99.5%—meaning only 0.5% of healthy individuals received a false positive result—and correctly identified the tissue of origin in 93% of cancer cases. However, sensitivity was stage-dependent, detecting only about 17% of stage I cancers but 91% of stage IV cancers. These results, while promising, highlight the challenge of early detection: the very cancers that would benefit most from early diagnosis are the hardest to detect.

The biological rationale for these approaches is grounded in the Molecular Basis of Cancer. Cancer arises through the accumulation of Genetic Mutation in genes that control cell division, apoptosis, and DNA repair. These mutations are the targets of liquid biopsy assays, and their detection in blood provides a direct window into the tumor's molecular state.

Limitations and Challenges

Despite its promise, liquid biopsy has significant limitations that must be acknowledged.

Sensitivity. ctDNA is present at very low concentrations in early-stage disease and may be undetectable in some patients with advanced cancer. Tumors that do not shed DNA efficiently into the bloodstream—such as certain brain tumors, where the blood-brain barrier limits ctDNA release—may produce false negative results. The sensitivity of ctDNA detection for stage I cancer is typically below 50%, meaning more than half of early-stage cancers would be missed.

Specificity and clonal hematopoiesis. A major challenge is distinguishing true tumor-derived mutations from benign mutations arising in normal blood cells. Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related phenomenon in which hematopoietic stem cells acquire mutations—often in genes like TP53, DNMT3A, and TET2—that expand clonally without causing cancer. These mutations appear in cfDNA and can be misinterpreted as tumor-derived, leading to false positive results. Careful analysis, including sequencing of matched white blood cells, is required to exclude CHIP.

Cost and accessibility. Comprehensive liquid biopsy tests, particularly those using NGS, are expensive—typically several hundred to several thousand dollars per test. While costs are decreasing, they remain a barrier to widespread adoption, particularly in low-resource settings.

Standardization. The liquid biopsy field lacks universal standards for pre-analytical variables (blood collection tubes, processing time, storage conditions), analytical methods, and reporting. Results can vary between laboratories using different platforms, complicating clinical interpretation and longitudinal monitoring.

Interpretation challenges. A positive liquid biopsy result confirms the presence of tumor-derived material, but it does not localize the tumor. Determining the tissue of origin requires additional analysis, such as methylation profiling, which is not always accurate. Furthermore, the clinical significance of low-level ctDNA positivity—particularly in the setting of minimal residual disease—is not always clear, and treatment decisions based on ctDNA alone may not always improve outcomes.

Common Misconceptions and Pitfalls

Several misconceptions about liquid biopsy persist among patients and, occasionally, clinicians.

"Liquid biopsy can replace tissue biopsy." This is not currently true. Liquid biopsy is complementary to tissue biopsy, not a replacement. Tissue biopsy provides histology—the microscopic appearance of the tumor—which is essential for diagnosis and classification. Liquid biopsy provides molecular information but cannot determine tumor grade, architecture, or invasion. Furthermore, a negative liquid biopsy does not rule out cancer; it may simply reflect low ctDNA levels or a tumor that does not shed DNA efficiently.

"A negative liquid biopsy means no cancer." False. Sensitivity is imperfect, particularly in early-stage disease. A negative result means no tumor-derived material was detected above the assay's limit of detection, not that the patient is cancer-free. Clinical decisions should never be based solely on a negative liquid biopsy result.

"Liquid biopsy is a screening test for everyone." While research is moving toward multi-cancer early detection, liquid biopsy is not yet approved for general population screening. The low incidence of cancer in asymptomatic individuals means that even a specificity of 99.5% would produce many false positives if applied to a healthy population, leading to unnecessary anxiety and invasive follow-up procedures.

"ctDNA levels correlate perfectly with tumor size." While ctDNA levels generally correlate with tumor burden, the relationship is not exact. Factors such as tumor vascularity, cell turnover rate, and clearance kinetics affect ctDNA concentration. A patient with a highly proliferative, well-vascularized tumor may have high ctDNA levels despite a small tumor, while a patient with a large but slowly dividing tumor may have low ctDNA levels.

"All mutations detected in ctDNA are actionable." Many mutations detected by comprehensive genomic profiling have no corresponding targeted therapy. The clinical utility of detecting a mutation depends on whether an effective drug exists and whether the patient's clinical context supports its use. Detection of a KRAS G12C mutation is actionable because the drug sotorasib targets this specific alteration; detection of a TP53 mutation, however, has no direct therapeutic implication because no drug currently targets mutant p53.

Future Directions and Summary

Liquid biopsy is transforming oncology by providing a non-invasive, repeatable, and comprehensive view of tumor biology. The field is advancing rapidly, with several emerging directions.

Multi-cancer early detection. The most ambitious application is a blood test that can screen for multiple cancer types simultaneously, potentially detecting cancers at stages when they are curable. The Galleri test and similar approaches use methylation patterns to both detect cancer and predict its tissue of origin. Large clinical trials are underway to evaluate whether such tests reduce cancer-specific mortality in screened populations.

Minimal residual disease monitoring. Post-operative ctDNA monitoring is being integrated into clinical trials as an endpoint for adjuvant therapy. The concept is straightforward: if ctDNA is detectable after surgery, residual disease is present, and additional treatment may be warranted. Several trials are testing whether ctDNA-guided adjuvant therapy improves outcomes compared with standard treatment.

Integration with immunotherapy. Liquid biopsy is being used to predict response to immune checkpoint inhibitors. Tumor mutational burden (TMB)—the number of mutations per megabase of DNA—can be estimated from ctDNA sequencing, and high TMB is associated with better response to immunotherapy. Additionally, ctDNA dynamics during immunotherapy may provide early evidence of response or resistance.

Epigenetic analysis. Beyond mutations, methylation patterns in ctDNA can reveal the tissue of origin, detect cancer-specific epigenetic alterations, and potentially identify the cell type of origin. This information is valuable for both early detection and monitoring.

Protein biomarkers. Combining ctDNA analysis with protein biomarkers such as CA-125, PSA, or CEA may improve sensitivity and specificity. Multi-analyte approaches that integrate genomic, epigenetic, and protein data are likely to be more powerful than any single biomarker.

In summary, liquid biopsy is a powerful tool that has already changed clinical practice in oncology. It enables non-invasive genotyping, real-time monitoring of tumor evolution, and early detection of resistance and recurrence. While it does not replace tissue biopsy, it complements it, providing information that tissue biopsy cannot—particularly the dynamic, whole-body view of cancer's molecular state. As technology improves and costs decrease, liquid biopsy is poised to become an increasingly central component of cancer care, from screening and diagnosis to treatment selection and surveillance.

Frequently Asked Questions

What is a liquid biopsy?

A liquid biopsy is a test that analyzes a sample of body fluid—most commonly blood—to detect cancer-related material such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes. It provides molecular information about a tumor without requiring an invasive tissue biopsy.

How does a liquid biopsy work?

A blood sample is collected and processed to separate plasma from cellular components. Cancer-derived material—such as ctDNA, CTCs, or exosomes—is then isolated from the plasma and analyzed using molecular techniques like PCR or next-generation sequencing. These methods detect specific genetic mutations, methylation changes, or protein markers that indicate the presence and characteristics of cancer.

What are the types of liquid biopsy?

The main types are ctDNA mutation analysis (detecting specific genetic mutations in circulating tumor DNA), CTC enumeration (counting intact tumor cells in blood), methylation-based assays (detecting epigenetic changes), and exosomal RNA analysis (examining RNA within tumor-derived vesicles). Each type provides different information and is suited to different clinical applications.

Is liquid biopsy painful?

No. Liquid biopsy is performed through a standard blood draw, similar to routine blood tests. The procedure involves inserting a needle into a vein, typically in the arm, and collecting a small volume of blood—usually 5 to 10 milliliters. There may be minor discomfort at the needle site, but the procedure is generally well tolerated and carries minimal risk.

What can liquid biopsy detect?

Liquid biopsy can detect genetic mutations, copy number alterations, and epigenetic changes in tumor-derived DNA; intact circulating tumor cells; and tumor-derived exosomes and microRNAs. Clinically, it is used to detect actionable mutations for treatment selection, monitor treatment response, detect resistance mutations, and identify minimal residual disease after surgery.

How is liquid biopsy different from a traditional biopsy?

A traditional tissue biopsy involves physically removing a piece of tumor tissue through a needle or surgical procedure. It is invasive, carries risks of complications, and provides a single snapshot of one tumor location. A liquid biopsy uses a blood sample to capture tumor-derived material from all tumor sites, is non-invasive and repeatable, and provides real-time information about tumor evolution.

Can liquid biopsy replace tissue biopsy?

Not currently. Liquid biopsy is complementary to tissue biopsy, not a replacement. Tissue biopsy provides essential histological information—the microscopic appearance of the tumor—that liquid biopsy cannot. Additionally, liquid biopsy has imperfect sensitivity, particularly in early-stage disease, and a negative result does not rule out cancer. In clinical practice, liquid biopsy is often used when tissue biopsy is not feasible or has failed, or to monitor tumor evolution over time.

Key Takeaways

Liquid biopsy is a non-invasive test that detects cancer-derived material—primarily circulating tumor DNA, circulating tumor cells, and exosomes—in body fluids such as blood.
The main advantages over tissue biopsy are safety, repeatability, real-time monitoring of tumor evolution, and the ability to capture tumor heterogeneity across all metastatic sites.
ctDNA analysis is the most clinically established application, used for detecting actionable mutations, monitoring treatment response, and identifying resistance mechanisms.
Liquid biopsy does not replace tissue biopsy; it complements it, and a negative liquid biopsy does not rule out cancer.
Current limitations include imperfect sensitivity in early-stage disease, the challenge of clonal hematopoiesis causing false positives, cost, and lack of standardization across laboratories.
Emerging applications include multi-cancer early detection tests, minimal residual disease monitoring, and integration with immunotherapy response prediction.
The field is advancing rapidly, with FDA-approved tests already in clinical use and large trials evaluating the impact of liquid biopsy on cancer outcomes.